← All indications
Retinal Vein Occlusion
Blockage of the RETINAL VEIN. Those at high risk for this condition include patients with HYPERTENSION; DIABETES MELLITUS; ATHEROSCLEROSIS; and other CARDIOVASCULAR DISEASES.
Drugs by status
Phase 4 trials (10)
Phase 3 trials (12)
Phase 2 trials (11)
Phase 1 trials (8)
Other trials (5)
Organizations
Organization Involved with Phase 4 Indications (33)
- Regeneron
- Bausch Health Companies
- Genentech
- Pfizer
- Novartis
- Allergan
- Bayer
- Ocular Therapeutix, Inc.
- Centre Hospitalier Intercommunal Creteil
- Greater Houston Retina Research
- Indiana University
- Nagoya City University
- Northern California Retina Vitreous Associates
- Retina Vitreous Associates of Florida
- Seoul National University
- St. Erik Eye Hospital
- The New York Eye & Ear Infirmary
- University of Rochester
- University of Toronto
- University of Bonn
- Asociación para Evitar la Ceguera en México
- Fukushima Medical University
- Tennessee Retina
- University of Vienna
- Retina Consultants Houston
- Palmetto Retina Center
- Sun Yat-Sen University
- Yeungnam University
- Ludwig Maximilians University
- Sungkyunkwan University
- +3 more
Organization Involved with Phase 3 Indications (40)
- Santen Inc.
- Chengdu Kanghong Biotech Co.,Ltd.
- Clearside Biomedical, Inc.
- Gene Signal SAS
- The EMMES Corporation
- Palo Alto Medical Foundation
- Rudolf Foundation Clinic
- National Eye Institute (NEI)
- Shahid Beheshti University of Medical Sciences
- Canadian Heart Research Centre
- University of London
- Johns Hopkins University
- Kyung Hee University
- Radboud University
- Retina Macula Institute
- Seoul Retina Investigator Group
- Texas Retina Associates
- University of Groningen
- Utrecht University
- University of Leipzig
- Instituto Universitario de Oftalmobiología Aplicada
- University of Cologne
- Leiden University
- University of Amsterdam
- Pennsylvania State University
- Kyungpook University
- Ospedale di Piacenza
- Ospedale di Gallarate
- University of Wisconsin
- Aleris Helse, Oslo
- +10 more
Organization Involved with Phase 2 Indications (38)
- Alimera Sciences
- Addmedica
- Wyeth
- Alcon
- Aerie Pharmaceuticals
- Aerpio Therapeutics
- Sanwa Kagaku Kenkyusho Co., Ltd.
- Sunshine Lake Pharma Co., Ltd.
- Taiwan Liposome Company
- Mid-Atlantic Retina Consultations, Inc.
- Hanscom, Thomas, M.D.
- Barnes Retina Institute
- California Retina Consultants
- Chang Gung University
- Manhattan Eye, Ear & Throat Hospital
- Ophthalmic Consultants of Boston
- Retina Associates of Florida, P.A.
- Tanta University
- Thomas Jefferson University
- University of Pecs
- University of Adelaide
- Peking University
- University of California, Davis
- University of Debrecen
- Taipei Veteran General hospital
- CHNO des Quinze-Vingts
- OHR Pharmaceutical
- Tianjin Medical University
- National Taiwan University
- Rafik Hariri University
- +8 more
Organization Involved with Phase 1 Indications (12)
- MediBeacon
- Retina Associates of Cleveland, Inc
- Baylor University
- Cornell University
- Katholieke Universiteit Leuven
- Stanford University
- Vitreous -Retina- Macula Consultants of New York (VRMNY)
- Retina Associates of Cleveland
- University of Paris
- Vitreoretinal Consultants
- Fovea Pharmaceuticals
- Targeted Therapy Technologies, LLC
Organization Involved with Other Experimental Indications (27)
- Kala Pharmaceuticals, Inc.
- Retina Research Institute, LLC
- Brian Burke, MPH
- Harvard University
- Kresge Eye Institute
- Kyoto University
- Queen's University, Belfast
- Retina Clinic, Sao Paulo, Brazil
- Retina-Vitreous Associates Medical Group
- St. Marianna University School of Medicine
- Tokyo Medical University
- University of Heidelberg
- University of Southern Denmark
- Yamagata University
- Illinois Retina Associates
- Long Island Vitreoretinal Consultants
- Mie University
- Renal Research Institute
- Retina Associates, Kansas City
- University of Copenhagen
- University of Sao Paulo
- West Coast Retina Medical Group, Inc.
- Toyota-Fonden
- AP Moeller Foundation
- Synoptik-Fonden
- He Eye Hospital
- He Eye Hospital, Shenyang, China